212 related articles for article (PubMed ID: 27174589)
1. Analytic validation of a clinical-grade PTEN immunohistochemistry assay in prostate cancer by comparison with PTEN FISH.
Lotan TL; Wei W; Ludkovski O; Morais CL; Guedes LB; Jamaspishvili T; Lopez K; Hawley ST; Feng Z; Fazli L; Hurtado-Coll A; McKenney JK; Simko J; Carroll PR; Gleave M; Lin DW; Nelson PS; Thompson IM; True LD; Brooks JD; Lance R; Troyer D; Squire JA
Mod Pathol; 2016 Aug; 29(8):904-14. PubMed ID: 27174589
[TBL] [Abstract][Full Text] [Related]
2. Novel dual-color immunohistochemical methods for detecting ERG-PTEN and ERG-SPINK1 status in prostate carcinoma.
Bhalla R; Kunju LP; Tomlins SA; Christopherson K; Cortez C; Carskadon S; Siddiqui J; Park K; Mosquera JM; Pestano GA; Rubin MA; Chinnaiyan AM; Palanisamy N
Mod Pathol; 2013 Jun; 26(6):835-48. PubMed ID: 23348902
[TBL] [Abstract][Full Text] [Related]
3. Novel, gross chromosomal alterations involving PTEN cooperate with allelic loss in prostate cancer.
Reid AH; Attard G; Brewer D; Miranda S; Riisnaes R; Clark J; Hylands L; Merson S; Vergis R; Jameson C; Høyer S; Sørenson KD; Borre M; Jones C; de Bono JS; Cooper CS
Mod Pathol; 2012 Jun; 25(6):902-10. PubMed ID: 22460813
[TBL] [Abstract][Full Text] [Related]
4. Integrated analysis of the genomic instability of PTEN in clinically insignificant and significant prostate cancer.
Murphy SJ; Karnes RJ; Kosari F; Castellar BE; Kipp BR; Johnson SH; Terra S; Harris FR; Halling GC; Klein JL; Nasir A; Bergstrahl E; Rangel LJ; Sukov WR; Vasmatzis G; Cheville JC
Mod Pathol; 2016 Feb; 29(2):143-56. PubMed ID: 26612463
[TBL] [Abstract][Full Text] [Related]
5. In prostate cancer needle biopsies, detections of PTEN loss by fluorescence in situ hybridization (FISH) and by immunohistochemistry (IHC) are concordant and show consistent association with upgrading.
Picanço-Albuquerque CG; Morais CL; Carvalho FL; Peskoe SB; Hicks JL; Ludkovski O; Vidotto T; Fedor H; Humphreys E; Han M; Platz EA; De Marzo AM; Berman DM; Lotan TL; Squire JA
Virchows Arch; 2016 May; 468(5):607-17. PubMed ID: 26861919
[TBL] [Abstract][Full Text] [Related]
6. PTEN losses exhibit heterogeneity in multifocal prostatic adenocarcinoma and are associated with higher Gleason grade.
Yoshimoto M; Ding K; Sweet JM; Ludkovski O; Trottier G; Song KS; Joshua AM; Fleshner NE; Squire JA; Evans AJ
Mod Pathol; 2013 Mar; 26(3):435-47. PubMed ID: 23018874
[TBL] [Abstract][Full Text] [Related]
7. PTEN genomic deletion is associated with p-Akt and AR signalling in poorer outcome, hormone refractory prostate cancer.
Sircar K; Yoshimoto M; Monzon FA; Koumakpayi IH; Katz RL; Khanna A; Alvarez K; Chen G; Darnel AD; Aprikian AG; Saad F; Bismar TA; Squire JA
J Pathol; 2009 Aug; 218(4):505-13. PubMed ID: 19402094
[TBL] [Abstract][Full Text] [Related]
8. A multicenter study shows PTEN deletion is strongly associated with seminal vesicle involvement and extracapsular extension in localized prostate cancer.
Troyer DA; Jamaspishvili T; Wei W; Feng Z; Good J; Hawley S; Fazli L; McKenney JK; Simko J; Hurtado-Coll A; Carroll PR; Gleave M; Lance R; Lin DW; Nelson PS; Thompson IM; True LD; Brooks JD; Squire JA
Prostate; 2015 Aug; 75(11):1206-15. PubMed ID: 25939393
[TBL] [Abstract][Full Text] [Related]
9. SPINK1 Overexpression in Localized Prostate Cancer: a Rare Event Inversely Associated with ERG Expression and Exclusive of Homozygous PTEN Deletion.
Huang KC; Evans A; Donnelly B; Bismar TA
Pathol Oncol Res; 2017 Apr; 23(2):399-407. PubMed ID: 27738792
[TBL] [Abstract][Full Text] [Related]
10. PTEN loss and p27 loss differ among morphologic patterns of prostate cancer, including cribriform.
Ronen S; Abbott DW; Kravtsov O; Abdelkader A; Xu Y; Banerjee A; Iczkowski KA
Hum Pathol; 2017 Jul; 65():85-91. PubMed ID: 28504208
[TBL] [Abstract][Full Text] [Related]
11. Genomic deletion of PTEN is associated with tumor progression and early PSA recurrence in ERG fusion-positive and fusion-negative prostate cancer.
Krohn A; Diedler T; Burkhardt L; Mayer PS; De Silva C; Meyer-Kornblum M; Kötschau D; Tennstedt P; Huang J; Gerhäuser C; Mader M; Kurtz S; Sirma H; Saad F; Steuber T; Graefen M; Plass C; Sauter G; Simon R; Minner S; Schlomm T
Am J Pathol; 2012 Aug; 181(2):401-12. PubMed ID: 22705054
[TBL] [Abstract][Full Text] [Related]
12. Association of ERG/PTEN status with biochemical recurrence after radical prostatectomy for clinically localized prostate cancer.
Mehra R; Salami SS; Lonigro R; Bhalla R; Siddiqui J; Cao X; Spratt DE; Palapattu GS; Palanisamy N; Wei JT; Chinnaiyan AM; Tomlins SA
Med Oncol; 2018 Oct; 35(12):152. PubMed ID: 30291535
[TBL] [Abstract][Full Text] [Related]
13. MAGI-2 in prostate cancer: an immunohistochemical study.
Goldstein J; Borowsky AD; Goyal R; Roland JT; Arnold SA; Gellert LL; Clark PE; Hameed O; Giannico GA
Hum Pathol; 2016 Jun; 52():83-91. PubMed ID: 26980016
[TBL] [Abstract][Full Text] [Related]
14. PTEN deletion is rare but often homogeneous in gastric cancer.
Mina S; Bohn BA; Simon R; Krohn A; Reeh M; Arnold D; Bokemeyer C; Sauter G; Izbicki JR; Marx A; Stahl PR
J Clin Pathol; 2012 Aug; 65(8):693-8. PubMed ID: 22639407
[TBL] [Abstract][Full Text] [Related]
15. Fluorescence in situ hybridization (FISH) provides estimates of minute and interstitial BAP1, CDKN2A, and NF2 gene deletions in peritoneal mesothelioma.
Brich S; Bozzi F; Perrone F; Tamborini E; Cabras AD; Deraco M; Stacchiotti S; Dagrada GP; Pilotti S
Mod Pathol; 2020 Feb; 33(2):217-227. PubMed ID: 31570769
[TBL] [Abstract][Full Text] [Related]
16. PTEN loss is associated with upgrading of prostate cancer from biopsy to radical prostatectomy.
Lotan TL; Carvalho FL; Peskoe SB; Hicks JL; Good J; Fedor H; Humphreys E; Han M; Platz EA; Squire JA; De Marzo AM; Berman DM
Mod Pathol; 2015 Jan; 28(1):128-137. PubMed ID: 24993522
[TBL] [Abstract][Full Text] [Related]
17. FISH analysis of 107 prostate cancers shows that PTEN genomic deletion is associated with poor clinical outcome.
Yoshimoto M; Cunha IW; Coudry RA; Fonseca FP; Torres CH; Soares FA; Squire JA
Br J Cancer; 2007 Sep; 97(5):678-85. PubMed ID: 17700571
[TBL] [Abstract][Full Text] [Related]
18. Hemizygous loss of NF2 detected by fluorescence in situ hybridization is useful for the diagnosis of malignant pleural mesothelioma.
Kinoshita Y; Hamasaki M; Yoshimura M; Matsumoto S; Iwasaki A; Nabeshima K
Mod Pathol; 2020 Feb; 33(2):235-244. PubMed ID: 31231129
[TBL] [Abstract][Full Text] [Related]
19. PTEN genomic deletion is an early event associated with ERG gene rearrangements in prostate cancer.
Bismar TA; Yoshimoto M; Vollmer RT; Duan Q; Firszt M; Corcos J; Squire JA
BJU Int; 2011 Feb; 107(3):477-85. PubMed ID: 20590547
[TBL] [Abstract][Full Text] [Related]
20. TMPRSS2-ERG gene fusion is rare compared to PTEN deletions in stage T1a prostate cancer.
Fisher KW; Zhang S; Wang M; Montironi R; Wang L; Baldrige LA; Wang JY; MacLennan GT; Williamson SR; Lopez-Beltran A; Cheng L
Mol Carcinog; 2017 Mar; 56(3):814-820. PubMed ID: 27500376
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
